Sage Therapeutics (SAGE) PT Raised to $140 at Canaccord Genuity
Tweet Send to a Friend
Canaccord Genuity raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $140.00 (from $81.00) while maintaining a Buy rating.Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
